bioAffinity Technologies, Inc.
BIAF
$10.50
$1.5717.58%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 18.99% | -27.09% | -27.85% | -38.47% | -47.05% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 18.99% | -27.09% | -27.85% | -38.47% | -47.05% |
| Cost of Revenue | 7.00% | -32.11% | -42.38% | -34.58% | -27.78% |
| Gross Profit | 67.14% | -12.93% | 7.33% | -44.64% | -74.45% |
| SG&A Expenses | 29.08% | 32.18% | 4.01% | -6.56% | -10.44% |
| Depreciation & Amortization | -45.58% | -25.94% | -19.47% | -25.05% | -25.08% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 28.02% | 10.89% | -8.23% | -13.54% | -15.62% |
| Operating Income | -32.57% | -37.68% | -6.46% | -16.16% | -20.49% |
| Income Before Tax | 16.51% | -36.92% | -5.64% | -152.61% | -91.54% |
| Income Tax Expenses | -- | -- | -- | 23.08% | 437.04% |
| Earnings from Continuing Operations | 17.11% | -36.47% | -5.75% | -152.45% | -92.43% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 17.11% | -36.47% | -5.75% | -152.45% | -92.43% |
| EBIT | -32.57% | -37.68% | -6.46% | -16.16% | -20.49% |
| EBITDA | -36.26% | -41.65% | -7.89% | -19.58% | 36.40% |
| EPS Basic | 87.30% | 83.55% | 88.33% | 2.24% | 8.76% |
| Normalized Basic EPS | 87.21% | 83.49% | 88.34% | 2.18% | 9.17% |
| EPS Diluted | 87.30% | 83.55% | 88.33% | 2.24% | 8.76% |
| Normalized Diluted EPS | 87.21% | 83.49% | 88.34% | 2.18% | 9.17% |
| Average Basic Shares Outstanding | 552.86% | 730.19% | 806.24% | 158.55% | 110.91% |
| Average Diluted Shares Outstanding | 552.86% | 730.19% | 806.24% | 158.55% | 110.91% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |